Skip to main content

Table 3 Unadjusted models for DFS and OS1

From: Cyclophosphamide- metabolizing enzyme polymorphisms and survival outcomes after adjuvant chemotherapy for node-positive breast cancer: a retrospective cohort study

Gene/Clinical Comparison Unadjusted DFS Unadjusted OS
   HR (95% CI) Wald P-value HR (95% CI) Wald P-value
CYP2B6 Any variant vs. All WT 1.10 (0.83, 1.46) 0.51 1.12 (0.83, 1.52) 0.46
CYP2C9 Any variant vs. All WT 0.97 (0.72, 1.29) 0.82 1.01 (0.75, 1.37) 0.94
CYP2D6 G/A vs. A/A 1.07 (0.57, 2.03) 0.83 1.30 (0.64, 2.62) 0.46
  G/G vs. A/A 0.89 (0.48, 1.65) 0.72 1.01 (0.51, 1.99) 0.98
CYP3A4 *1B/*1A vs. *1A/*1A 1.70 (1.10, 2.63) 0.02 1.21 (0.74, 1.96) 0.45
  *1B/*1B vs *1A/*1A 1.96 (0.96, 3.98) 0.07 1.64 (0.77, 3.50) 0.20
CYP3A5 *3/*1 vs. *1/*1 0.76 (0.36, 1.59) 0.47 1.18 (0.49, 2.84) 0.72
  *3/*3 vs. *1/*1 0.74 (0.38, 1.45) 0.38 1.18 (0.52, 2.67) 0.69
CYP3A5 *6/*1 vs. *1/*1 2.71 (1.01, 7.32) 0.05 2.47 (0.92, 6.66) 0.07
GSTM1 Null vs. Non-null 0.71 (0.54, 0.93) 0.02 0.71 (0.53, 0.94) 0.02
GSTT1 Null vs. Non-null 1.41 (1.00, 1.97) 0.05 1.31 (0.91, 1.88) 0.14
GSTP1 Any Var vs. All WT 1.03 (0.79, 1.36) 0.81 1.18 (0.88, 1.57) 0.27
CYP-GST genotype groups Unfavorable vs. Intermediate or Favorable 1.29 (0.97-1.72) 0.08 1.32 (0.98-1.79) 0.07
Lymph node Continuous 1.02 (1.00, 1.04) 0.06 1.02 (1.00, 1.04) 0.10
Tumor size Continuous 1.00 (1.00, 1.01) 0.36 1.00 (1.00, 1.01) 0.13
Age Continuous 0.99 (0.97, 1.00) 0.10 0.99 (0.97, 1.01) 0.28
ER Pos vs. Neg 0.79 (0.60, 1.04) 0.10 0.78 (0.58, 1.04) 0.10
PR Pos vs. Neg 0.82 (0.62, 1.07) 0.15 0.88 (0.66, 1.17) 0.37
Race Black vs. White 1.44 (0.84, 2.48) 0.19 1.41 (0.80, 2.49) 0.23
  Other vs. White 1.49 (0.83, 2.68) 0.18 1.20 (0.64, 2.28) 0.57
Arm CAF+HDC vs. CAF 0.79 (0.60, 1.03) 0.08 0.93 (0.70, 1.23) 0.59
  1. 1Cox Regression
  2. CAF: cyclophosphamide, doxorubicin, fluorouracil; DFS: disease free survival; ER: estrogen receptor; HDC: high dose chemotherapy; HR: hazard ratio; PR: progesterone receptor; OS: overall survival